期刊文献+

唑来膦酸针与伊班膦酸钠针治疗骨肿瘤的临床效果分析 被引量:2

Clinical Observation of Zoledronic Acid and Ibandronate in Treatment of Bone Neoplasms
下载PDF
导出
摘要 目的 比较唑来膦酸针与伊班膦酸钠针治疗骨肿瘤患者的临床效果和医疗费用。方法 选取2011年9月~2014年9月间收治入院的35例骨肿瘤患者为研究对象,随机分为A组(18例)和B组(17例),A组患者采用唑来膦酸针治疗,B组患者采用伊班膦酸钠针治疗,比较两组患者的临床疗效、不良反应和医疗费用。结果 B组的疼痛缓解率及生活质量改善率显著优于A组(P〈0.05),不良反应发生率显著低于A组(P〈0.05),且B组患者产生的总医疗费用低于A组(P〈0.05)。结论 与唑来膦酸针比较,伊班膦酸钠针治疗骨肿瘤的临床疗效更显著,不良反应更少且产生的医疗费用较低,值得临床推广应用。 Objective To evaluate the efficacy of zoledronic acid and ibandronate for bone neoplasms. Methods We selected 35 cases of patients with bone neoplasms from our hospital as the study objects. They were randomly divided into two groups: group A (18 eases) and group B (17 eases). Patients in group A were treated with zoledronic acid, while patients in group B were treated with ibandronate sodium. The improvement of pain and the incidence of adverse reactions in the two groups were compared and analyzed. Results The rates of pain relief and improvement of quality of life in group B was significantly higher than in group A (P〈0.05). The incidence of adverse reactions in group B was significantly lower than in group A (P〈0.05). And the total medical cost of patients in group B was less than that in group A (P〈0.05). Conclusion Compared with zoledronic acid, ibandronate had better clinical curative effect in treatment of bone tumors. It also had less adverse reaction and less medical expenses, so it is worthy of cfinieal application.
出处 《肿瘤药学》 CAS 2015年第6期454-457,共4页 Anti-Tumor Pharmacy
基金 国家自然科学基金资助项目(81202730)
关键词 伊班膦酸 唑来膦酸 骨肿瘤 疗效分析 Ibandronate Zoledronate Bone neoplasms Curative effect analysis
  • 相关文献

参考文献17

二级参考文献99

  • 1吾甫尔·艾克木,王若峥,王多明.卡培他滨化疗同步放射治疗局部晚期直肠癌的疗效观察[J].中国全科医学,2009,12(15):1426-1427. 被引量:9
  • 2戴月华,张海军.唑来膦酸加速肾功能损害引起死亡1例[J].中国药师,2006,9(9):814-814. 被引量:7
  • 3Akhtari M, Mensuri J, Newman KA, et al. Biology of breast cancer bone metastasis [J]. Cancer Biol Ther, 2008, 7 ( 1 ) : 3 - 9.
  • 4Aoki J, Inoue T, Tomiyoshi K, et al. Nuclear imaging of bone tumors: FDG - PET [ J ]. Semin Musculoskelet Radiol, 2001, 5 (2) : 183 -187.
  • 5Rosen LS, Gordon DH, Dugan W, et al. Zoledrenic acid is superior to pamidrenate for the treatment of bone metastases in breast carcinoma patients with at least osteolytic lesion [J]. Cancer, 2004, 100 (1): 36-43.
  • 6Jagder SP, Croucher PI, Coleman RE. Zoledronate induces apoptosis of breast cancer ceils in vitro evidence for additive and synergistic effects with taxol and tamoxifen [J]. Proc Am Soc Clin Oncol, 2000, 19 (6) : 664.
  • 7Blum JL, Dietas V, Lo Russo PM, et al. Muhicenter, phase II study of capecitabine in taxane - pretreated metastatic breast carcinoma [J]. Cancer, 2001, 92: 1759.
  • 8Fumoleau P, Largillier R, Clippe C, et al. Muhicantre, phase Ⅱ study evaluating capecitabine monothempy in patients with anthracycline and taxane pretreated metastatic breast cancer [J].EurJ Cancer, 2004, 40 (4) : 536 -542.
  • 9Coleman RE.Bisphosphonates:clinical experience[J].Oncologist,2004,9(Suppl 4):14-27.
  • 10Clezardin P.The antitumor potential of bisphosphonates[J].Semin Onco1,2002,29(suppl.21):33-42.

共引文献73

同被引文献27

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部